PBE – Invesco Dynamic Biotechnology & Genome ETF
Invesco Dynamic Biotechnology & Genome ETF (PBE) is a Health ETF, issued by Invesco, $268M in assets, 0.58% expense ratio.
Returns as of Oct 23, 2026: 1 week +2.7%, 1 year +22.2%.
Tracks index of U.S. biotechnology and genome companies engaged in research, development, manufacture, and marketing of biotech products and services.
Top holdings
- ILMN – Illumina Inc, 5.8%
- GILD – Gilead Sciences Inc, 4.9%
- AMGN – Amgen Inc, 4.9%
- UTHR – United Therapeutics Corporation, 4.9%
- INCY – Incyte Corporation, 4.8%
- REGN – Regeneron Pharmaceuticals Inc, 4.8%
- BIIB – Biogen Inc, 4.6%
- ALNY – Alnylam Pharmaceuticals Inc, 4.1%
- FOLD – Amicus Therapeutics Inc, 3.9%
- DVAX – Dynavax Technologies Corporation, 3.7%
- ACAD – ACADIA Pharmaceuticals Inc, 3.0%
- TECH – Bio-Techne Corp, 3.0%
- MNKD – MannKind Corp, 2.9%
- COLL – Collegium Pharmaceutical Inc, 2.8%
- EXEL – Exelixis Inc, 2.8%
- BMRN – Biomarin Pharmaceutical Inc, 2.7%
- CPRX – Catalyst Pharmaceuticals Inc, 2.7%
- IONS – Ionis Pharmaceuticals Inc, 2.7%
- RPRX – Royalty Pharma Plc, 2.7%
- BCRX – BioCryst Pharmaceuticals Inc, 2.6%
- RGEN – Repligen Corporation, 2.6%
- TGTX – TG Therapeutics Inc, 2.6%
- NBIX – Neurocrine Biosciences Inc, 2.6%
- HALO – Halozyme Therapeutics Inc, 2.6%
- PTGX – Protagonist Therapeutics Inc, 2.6%